Abiopharma

🔍 MACK DAVID J. (Director)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2025-08-31

Detailed Transactions and Holdings:

• Acquired 1,693 shares of Common Stock (Direct)
  Date: 2025-08-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,930.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,693 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,387.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.